# Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.

> **NCT05811949** · — · COMPLETED · sponsor: **IRCCS Centro Neurolesi Bonino Pulejo** · enrollment: 52 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Dimethyl Fumarate 240 MG [Tecfidera]

## Key facts

- **NCT ID:** NCT05811949
- **Lead sponsor:** IRCCS Centro Neurolesi Bonino Pulejo
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-24
- **Primary completion:** 2022-10-11
- **Final completion:** 2023-06-07
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05811949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05811949, "Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05811949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*